Eyenovia Initiates Process To Explore Strategic Alternatives To Maximize Shareholder Value
Eyenovia Initiates Process To Explore Strategic Alternatives To Maximize Shareholder Value
Eyenovia启动了探索战略替代方案的进程，以最大限度地提高股东价值
The company announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (MicroPine). In conjunction with the strategic process and focus on its late stage MicroPine asset, Eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expenses while continuing to support meaningful value generation from the company's two FDA-approved products.
该公司宣布计划加速开发其潜在的数十亿美元儿童进行性近视产品（MicroPine）。结合战略流程和专注于其后期的MicroPine资产，Eyenovia重申了其直接的商业化机会和企业储蓄，旨在减少运营开支，同时继续支持该公司两款获得美国食品药品管理局批准的产品创造有意义的价值。